Pharvaris price target lowered to $31 from $35 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Pharvaris to $31 from $35 and keeps an Outperform rating on the shares. Most notable in the Pharvaris’ Q1 financial results, the company will meet with FDA in Q2 to finalize Phase 3 prophylactic study design. The firm anticipates few surprises to emerge and looks for pivotal studies to commence once alignment is reached. Wedbush continues to see Pharvaris as a differentiated player in the HAE therapeutic and a good fit in its “HAE basket.”